Status:

COMPLETED

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

MALE

21-50 years

Phase:

PHASE1

Brief Summary

Study to assess safety, tolerability and pharmacokinetics (PK) of single intravenous (i.v.) doses of BIIB 722 CL

Eligibility Criteria

Inclusion

  • Healthy males
  • 21 to 50 years of age
  • Broca index \>= -20% and \<= +20%
  • Written informed consent according to Good Clinical Practice (GCP) and local legislation

Exclusion

  • Any finding of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG)) deviating from normal and of clinical relevance
  • History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
  • Diseases of the central nervous system or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study
  • Use of any drugs, which might influence the results of the trial within two weeks prior to administration or during the trial
  • Participation in another trial with an investigational drug (\<= two months prior to administration or during trial)
  • Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (\> 60 g/day)
  • Drug abuse
  • Blood donation (\>= 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within the last week before the study)
  • Any laboratory value outside the reference range of clinical relevance

Key Trial Info

Start Date :

April 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT02224079

Start Date

April 1 2002

Last Update

August 25 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.